Cancer early‑detection company Grail announced a securities purchase agreement expected to raise approximately $325 million in a private placement, citing new and existing institutional investors and pre‑funded warrants priced at $70.05 each. The company said proceeds plus existing resources and a conditional Samsung investment will fund operations into 2030. Grail named participating investors including Deep Track Capital, Farallon and Hims & Hers and said funds will support commercial activities, reimbursement efforts and working capital. The financing follows public trading strength and an earlier disclosed planned Samsung investment. Management framed the round as strategic runway to scale reimbursement and sales channels for multi‑cancer early detection tests while continuing R&D and payer engagement.